NCT06644781
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 10 versions: 10 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 17 words
- Trial sites expanded: 132 → 168 locations
- Secondary endpoints: details revised at 4 of 11 entries
- Collaborators: details revised at 1 of 1 entry
- Minor Trial sites expanded: 88 → 132 locationsv9
- Minor Study sites: 46 to 88v8
- Minor Study sites: 20 to 46v7
- Minor Study sites: 15 to 20v6
Show 4 earlier versionsHide 4 earlier versions
- Minor Study sites: 9 to 15v5
- Minor Study sites: 6 to 9v4
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 6
- Start date changed from estimate of Feb 28, 2025 to Mar 27, 2025
Notable Eligibility criteria shortened, about 136 wordsv2 Show 5 more changesShow less
- Primary completion date: May 30, 2029 to Jun 1, 2028
- Study completion date: Oct 30, 2029 to Nov 1, 2029
- Interventions: Docetaxel (Drug), Ifinatamab deruxtecan (Drug), Irinotecan (Drug), Paclitaxel (Drug) to Docetaxel (Drug), Ifinatamab deruxtecan (Drug), Irinotecan hydrochloride (HCl) (Drug), Paclitaxel (Drug)
- Secondary endpoints: details revised at 9 of 11 entries
- Study title expanded, about 5 words
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (11)
Show 6 moreShow less
Arms and interventions
Participants who are randomized to receive an intravenous infusion of I-DXd 12 mg/kg on Day 1 of every 21-day cycle (Q3W).
Participants who are randomized to receive an intravenous infusion of investigator's choice of chemotherapy (docetaxel, paclitaxel, and irinotecan HCl).
Drugs: Ifinatamab deruxtecan, Docetaxel, Paclitaxel, Irinotecan hydrochloride (HCl)
Sites
168 sites in 17 countries
China 30, France 17, Japan 17, Spain 14, United States 14, Germany 11, Italy 11, United Kingdom 11, South Korea 10, Romania 7, Belgium 6, Taiwan 5, Netherlands 4, Denmark 3, Norway 3, Poland 3, Sweden 2